Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.

Blood Adv · 2023 · PMC10172873 · PMID 36441905

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

a nonsignificant trendP value = .069so close (0.05 < p ≤ 0.1)

Receipt of venetoclax-based therapy was associated with a nonsignificant trend toward improved OS, similar to that observed with IC (HR, 0.51; 95% CI, 0.24-1.05; P value = .069).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.